<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Persistent or recurrent Cushing disease: Surgical adrenalectomy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Persistent or recurrent Cushing disease: Surgical adrenalectomy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Persistent or recurrent Cushing disease: Surgical adrenalectomy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H362181283"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of choice for patients with Cushing disease (corticotropin [ACTH]-secreting pituitary tumor) is transsphenoidal surgery and resection of the pituitary tumor. However, for patients with persistent or recurrent Cushing disease, adrenalectomy, which can be achieved either surgically or medically (with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>), is sometimes recommended for definitive cure.</p><p>Surgical adrenalectomy for persistent or recurrent Cushing disease is reviewed here. An overview of the treatment of Cushing syndrome, medical therapy of hypercortisolism, and primary therapy for Cushing disease are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/174.html" rel="external">"Overview of the treatment of Cushing syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a> and  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation"</a>.)</p><p class="headingAnchor" id="H1240291812"><span class="h1">GENERAL APPROACH TO CUSHING DISEASE</span><span class="headingEndMark"> — </span>Cushing disease is caused by pituitary corticotropin (ACTH)-secreting tumors. These corticotroph tumors are almost always benign and are usually microadenomas (ie, &lt;10 mm in diameter). The progressive stages of treatment that may be required to cure a patient of Cushing disease are shown in the algorithm (<a class="graphic graphic_algorithm graphicRef76949" href="/z/d/graphic/76949.html" rel="external">algorithm 1</a>). This approach is largely consistent with the Endocrine Society Clinical Practice Guideline [<a href="#rid1">1</a>].</p><p>Transsphenoidal microadenomectomy is currently the treatment of choice for Cushing disease. A neurosurgeon with expertise in transsphenoidal surgery for Cushing patients can achieve an initial cure rate of 80 to 90 percent with microadenomas but less than 60 percent with macroadenomas. (See  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Transsphenoidal surgery'</a>.)</p><p>For patients with clear persistent disease after transsphenoidal surgery or later recurrence, there are five therapeutic options (see  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Treatment if surgery fails'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Repeat surgery of residual corticotroph adenoma, particularly if residual tumor is visible on magnetic resonance imaging (MRI). However, reoperation has a lower success rate than initial surgery, and many patients develop other pituitary hormone deficiencies as a result of the second procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Irradiation of the pituitary gland. Radiation therapy may decrease the occurrence of Nelson syndrome in patients not cured by irradiation for whom adrenalectomy becomes necessary. (See  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Pituitary irradiation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy with adrenal enzyme inhibitors or other agents. (See  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical adrenalectomy with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>, an adrenolytic agent, may be used during or after pituitary irradiation in patients with Cushing disease. (See  <a class="medical medical_review" href="/z/d/html/119.html" rel="external">"Medical therapy of hypercortisolism (Cushing's syndrome)", section on 'Mitotane'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical adrenalectomy. (See <a class="local">'Surgical adrenalectomy'</a> below.)</p><p></p><p>The choice for therapy is individualized. For example, a young woman desiring fertility might choose to have adrenalectomy or repeat transsphenoidal exploration to avoid hypogonadism associated with radiotherapy and the teratogenicity of <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>. A patient with extreme hypercortisolism might choose adrenalectomy to achieve rapid control.</p><p class="headingAnchor" id="H362181869"><span class="h1">SURGICAL ADRENALECTOMY</span></p><p class="headingAnchor" id="H3904226301"><span class="h2">Preoperative pituitary irradiation</span><span class="headingEndMark"> — </span>We suggest pituitary irradiation prior to bilateral adrenalectomy in patients with Cushing disease and radiologically detectable residual corticotroph tumor or in whom microscopic dural invasion by tumor is documented (to decrease the risk of Nelson syndrome). We do not administer pituitary irradiation to patients without residual tumor on pathology or MRI scan. (See <a class="local">'Prevention'</a> below.)  </p><p class="headingAnchor" id="H3363151022"><span class="h2">Choice of procedure</span><span class="headingEndMark"> — </span>We suggest bilateral total surgical adrenalectomy as the definitive treatment for patients in whom rapid cure of hypercortisolism is necessary or when all other therapies have failed [<a href="#rid2">2-4</a>].</p><p>Bilateral adrenalectomy has also been successfully used in several pregnant women with Cushing syndrome [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/139.html" rel="external">"Diagnosis and management of Cushing syndrome during pregnancy", section on 'Management'</a>.)</p><p>There had been reluctance historically to recommend bilateral adrenalectomy in patients with refractory Cushing disease for several reasons, all of which have become less of a concern:</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical morbidity with open adrenalectomy – Complication rates are now much lower as a result of laparoscopic adrenalectomy. (See  <a class="medical medical_review" href="/z/d/html/15027.html" rel="external">"Adrenalectomy techniques", section on 'Approach by indication'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The risk of Nelson syndrome (corticotroph tumor progression with increased corticotropin [ACTH]) can now be monitored with MRI. (See <a class="local">'Nelson syndrome'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about impaired quality of life related to the postoperative need for chronic glucocorticoid and mineralocorticoid replacement. However, patients who undergo bilateral adrenalectomy appear to experience an improvement in quality of life that is similar to that in patients initially cured by transsphenoidal surgery [<a href="#rid6">6</a>]. (See <a class="local">'Quality of life'</a> below.)</p><p></p><p>In contrast to bilateral adrenalectomy, unilateral or subtotal adrenalectomy is virtually <strong>never </strong>successful in ACTH-dependent Cushing syndrome, unless the patient has improved in response to pituitary irradiation (ACTH secretion is partially inhibited) or the adrenalectomy becomes complete, because of subsequent infarction of the remnant [<a href="#rid2">2</a>]. Therefore, we do <strong>not</strong> suggest this approach.</p><p>The failure of incomplete adrenalectomy is related to the ability of the adrenal remnant eventually to become hyperplastic. For the same reason, total adrenalectomy with subcutaneous adrenal autotransplantation is likely to fail; three of eight patients treated with this technique developed recurrent Cushing syndrome in one report [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H362181891"><span class="h3">Surgical approach</span><span class="headingEndMark"> — </span>The laparoscopic approach, which can be done via either the anterior or posterior approaches, has become standard, as hospital stays appear to be shorter (usually one to five days) and complications fewer, as compared with open surgery [<a href="#rid8">8-10</a>]. Regardless of the approach used, the glands must be removed en bloc. Care also must be taken to ensure that the fragile capsule is not broken [<a href="#rid11">11</a>] because cells spilled locally can become hyperplastic and cause recurrent disease; they are then not usually amenable to surgical removal. (See  <a class="medical medical_review" href="/z/d/html/15027.html" rel="external">"Adrenalectomy techniques", section on 'Selection of operative approach'</a>.)</p><p class="headingAnchor" id="H362181898"><span class="h2">Hormone replacement</span><span class="headingEndMark"> — </span>On the day of adrenalectomy, most surgeons administer glucocorticoids (50 to 100 mg <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, intravenous [IV], on call to the operating room and every eight hours). Generally, the dose is tapered rapidly to 50 and then 25 mg IV every eight hours over the next two days. This agent and dose provide both glucocorticoid and mineralocorticoid coverage.</p><p>By the third postoperative day, most patients are able to take oral replacement doses of <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> and <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> (see  <a class="medical medical_review" href="/z/d/html/155.html" rel="external">"Treatment of adrenal insufficiency in adults"</a>). A daily dose of 15 to 25 mg hydrocortisone or its equivalent is thought to be optimal glucocorticoid replacement (<a class="graphic graphic_table graphicRef78904" href="/z/d/graphic/78904.html" rel="external">table 1</a>) [<a href="#rid12">12,13</a>].</p><p>However, many patients receive excessive doses of glucocorticoid therapy after adrenalectomy [<a href="#rid12">12-14</a>]. As an example, in a report of 14 women receiving glucocorticoids post-adrenalectomy for Cushing disease, bone mineral density was similar, body fat was higher, and fat-free mass was lower when compared with 14 control women of similar age, body mass index (BMI), and menopausal status [<a href="#rid14">14</a>]. The replacement glucocorticoid doses were: <a class="drug drug_general" data-topicid="9297" href="/z/d/drug information/9297.html" rel="external">cortisone acetate</a> (n = 10) 15 to 50 mg per day, <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> (n = 1) 20 mg per day, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (n = 2) 5 or 7.5 mg per day, or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (n = 1) 0.5 mg per day, an average of 27.3 mg hydrocortisone equivalents per day.</p><p class="headingAnchor" id="H3766561473"><span class="h2">Postoperative management</span><span class="headingEndMark"> — </span>After adrenalectomy in Cushing disease, one should not wait for the occurrence of Nelson syndrome; modern imaging allows early detection and management of corticotroph tumor progression.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assess for cure </strong>– Between three days and two weeks after adrenalectomy (or possibly later), if clinical features of Cushing syndrome recur, a morning blood sample should be drawn before the replacement glucocorticoid dose is taken to confirm that serum cortisol is undetectable. Up to 3 percent of patients have recurrence because of an adrenal remnant [<a href="#rid15">15</a>]. Surgical removal of the remnant depends on whether it can be located. Medical therapy can be given as an alternative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitor for Nelson syndrome </strong>–<strong> </strong>In addition, because of the potential risk of corticotroph tumor progression (Nelson syndrome), we suggest that adrenalectomized patents be followed with MRI of the pituitary and plasma ACTH measurements, annually for seven years, and then intermittently if there has been no tumor progression [<a href="#rid16">16-21</a>]. (See <a class="local">'Nelson syndrome'</a> below.)</p><p></p><p class="headingAnchor" id="H874893986"><span class="h1">OUTCOMES</span></p><p class="headingAnchor" id="H3217990448"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Patients show improved quality of life after bilateral adrenalectomy that is similar to that seen after transsphenoidal surgery [<a href="#rid6">6,8,15</a>]. However, other studies have reported impaired quality of life [<a href="#rid9">9,22</a>].</p><p class="headingAnchor" id="H362181912"><span class="h2">Nelson syndrome</span><span class="headingEndMark"> — </span>Patients who have had bilateral adrenalectomy for Cushing disease may develop corticotroph tumor progression, defined as an enlarging pituitary tumor (new mass, or an increase of at least 2 mm in diameter) on MRI. In one study, this was noted after adrenalectomy in nearly 50 percent of patients without prior pituitary irradiation [<a href="#rid16">16</a>]. Most changes were noted within three years of surgery. Only four of these patients developed a macroadenoma, and only one presented with pituitary apoplexy. Logistic regression analysis showed that patients with a shorter duration of Cushing syndrome and higher postoperative plasma corticotropin (ACTH) concentrations were more likely to develop tumor progression.</p><p>Before MRI allowed for measurement of small changes in tumor size, Nelson syndrome was defined using sellar radiograms as the association of an enlarging pituitary tumor with progressive hyperpigmentation caused by very high plasma ACTH concentrations after bilateral adrenalectomy for Cushing syndrome [<a href="#rid23">23</a>]. In addition to hyperpigmentation, other clinical manifestations due to the enlarging tumor were common, including headaches, visual field defects, and, sometimes, cranial nerve palsies [<a href="#rid24">24</a>]. Most patients are now diagnosed at an earlier stage by MRI [<a href="#rid16">16</a>]. Therefore, symptoms related to the tumor itself are somewhat less common, but hyperpigmentation is still an important clinical manifestation [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H362181919"><span class="h3">Incidence</span><span class="headingEndMark"> — </span>When judged using sellar radiograms, Nelson syndrome was reported in up to 25 percent of adults and in over 50 percent of children with Cushing disease after total adrenalectomy without prior pituitary irradiation [<a href="#rid17">17,24-30</a>], and in 47 percent of similar patients evaluated by MRI [<a href="#rid16">16</a>]. It is less common after medical adrenalectomy with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a> [<a href="#rid31">31,32</a>]. Data are conflicting on the impact of patient age on the risk of developing Nelson syndrome [<a href="#rid16">16,33</a>]. In one study, few patients developed corticotroph tumor progression more than seven years after adrenalectomy, suggesting that monitoring frequency could decrease at this time [<a href="#rid16">16</a>].</p><p>There are no predictive clinical or laboratory indexes for the development of Nelson syndrome except the plasma ACTH value. Plasma ACTH concentrations increase much more in patients who subsequently develop Nelson syndrome than in those who do not:</p><p class="bulletIndent1"><span class="glyph">●</span>During the first year after adrenalectomy while taking equivalent glucocorticoid replacement therapy (greater than 700 pg/mL [154 pmol/L]) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One report suggested that the risk of Nelson syndrome was greater in patients with suboptimal glucocorticoid replacement therapy [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H362181926"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>Corticotroph progression becomes apparent several months to many years after adrenalectomy, the average being approximately three years. The pathogenesis of these tumors is uncertain. They presumably represent the accelerated growth of ACTH-secreting cells in preexisting microadenomas when the effect of glucocorticoid negative feedback inhibition is reduced [<a href="#rid35">35</a>].</p><p>Other than differences attributable to the larger tumor cell mass and lack of glucocorticoid inhibition of adenomas causing Nelson syndrome, these tumors are similar to microadenomas causing Cushing syndrome with regard to light microscopic structure, ultrastructure, response to corticotropin-releasing hormone (CRH), and the proopiomelanocortin products they produce. However, it is not clear why only some, but not all, tumors continue to grow.</p><p class="headingAnchor" id="H362181933"><span class="h3">Biochemical criteria</span><span class="headingEndMark"> — </span>Plasma ACTH concentrations in patients with Nelson syndrome range from as low as 800 pg/mL (175 pmol/L) to values that may exceed 25,000 pg/mL (5500 pmol/L). Some investigators have used plasma ACTH values as low as 200 pg/mL, in addition to hyperpigmentation, as the criteria for diagnosing Nelson syndrome [<a href="#rid36">36</a>]. These values are much higher than the normal 8 AM values for ACTH (20 to 50 pg/mL [4.4 to 11.3 pmol/L]) and overlap with values that are normally seen in patients after adrenalectomy. (See  <a class="medical medical_review" href="/z/d/html/171.html" rel="external">"Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides"</a>.)</p><p class="headingAnchor" id="H2714456616"><span class="h3">Prevention</span><span class="headingEndMark"> — </span>We suggest pituitary irradiation before adrenalectomy in patients with Cushing disease with radiologically detectable residual corticotroph tumor or in whom microscopic dural invasion by tumor is documented. It has been reported to prevent this complication in some [<a href="#rid34">34,36-38</a>], but not all [<a href="#rid3">3,28</a>], studies.</p><p class="bulletIndent1"><span class="glyph">●</span>The protection is not complete, as some adrenalectomized patients do develop Nelson syndrome despite prior pituitary irradiation [<a href="#rid3">3,28,34,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is one report of fatal Nelson syndrome with accelerated tumor growth following pituitary irradiation; a P53 mutation was found in that tumor [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H362181940"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Once the tumor in a patient with Nelson syndrome becomes large enough to expand the sella, it is locally invasive, difficult to cure, and may develop into a pituitary carcinoma. Transsphenoidal surgery should be performed before the tumor becomes a macroadenoma [<a href="#rid16">16,20,21,40,41</a>].</p><p>With careful follow-up, extrasellar extension should be prevented by early intervention. In older series that did not use this approach, a transcranial approach was sometimes necessary for tumors with extrasellar extension (14 of 43 patients in one series, 33 percent) [<a href="#rid42">42</a>]. Success rates vary from 10 to 70 percent [<a href="#rid24">24,42,43</a>]. Surgical morbidity is significant with up to 70 percent developing panhypopituitarism, 15 percent a cerebrospinal fluid leak, and 8 percent develop meningitis [<a href="#rid24">24,43</a>].</p><p>Progression of very large Nelson syndrome tumors may occur even after surgical intervention [<a href="#rid43">43</a>]. Therefore, postoperative radiation is suggested for patients with any evidence of residual tumor. This type of radiation chosen is typically dictated by availability, cost, and patient preference regarding treatment time.</p><p class="bulletIndent1"><span class="glyph">●</span>The optimal type of radiation therapy has not been determined. In one report of conventional radiation in 15 patients with Nelson syndrome, satisfactory results, including regression of hyperpigmentation and tumor shrinkage, were reported in 14 of the 15 patients followed for a median of 9.6 years [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stereotactic radiosurgery has been used [<a href="#rid45">45,46</a>]. In one report of 10 patients, one type of stereotactic radiosurgery stopped tumor growth [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study of 22 patients, tumor volume decreased in 12, had no change in 8, and increased in 2 [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/7063.html" rel="external">"Stereotactic cranial radiosurgery"</a>.)</p><p></p><p>Medical therapy of Nelson syndrome is relatively ineffective, and therefore, we do not suggest its use. Although there is a case report of sustained remission with <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a> [<a href="#rid48">48</a>], neither this drug nor <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproic acid</a> had a significant acute effect on ACTH secretion in six women with Nelson syndrome in one report [<a href="#rid49">49</a>]. In contrast, <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a> lowered plasma ACTH concentrations acutely by 52 percent in these women. Long-term <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a> administration decreased ACTH levels and tumor size in two patients [<a href="#rid50">50,51</a>]. <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">Rosiglitazone</a> was effective in only 1 of 19 patients [<a href="#rid52">52-55</a>].</p><p><a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">Naloxone</a> and <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> are not effective. The somatostatin analog <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> reduced ACTH secretion and tumor size in a few patients with Nelson syndrome for as long as two years [<a href="#rid33">33</a>].</p><p>One report showed regression of tumor size after <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a> treatment in two of four patients with aggressive corticotroph tumors or carcinoma [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1339658501"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112709.html" rel="external">"Society guideline links: Diagnosis and treatment of Cushing syndrome"</a>.)</p><p class="headingAnchor" id="H362183267"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transsphenoidal surgery </strong>–<strong> </strong>The treatment of choice for patients with Cushing disease (corticotropin [ACTH]-secreting pituitary tumor) is transsphenoidal surgery and resection of the pituitary tumor. The progressive stages of treatment that may be required to cure a patient of Cushing disease are shown in the algorithm (<a class="graphic graphic_algorithm graphicRef76949" href="/z/d/graphic/76949.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent or recurrent disease </strong>–<strong> </strong>For patients with persistent or recurrent Cushing disease, adrenalectomy, which can be achieved either surgically or medically (with <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>), is sometimes recommended for definitive cure. (See <a class="local">'General approach to Cushing disease'</a> above.)  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral surgical adrenalectomy </strong>–<strong> </strong>We suggest bilateral total surgical adrenalectomy as the definitive treatment for patients in whom rapid cure of hypercortisolism is necessary or when all other therapies have failed (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Surgical adrenalectomy'</a> above.)</p><p></p><p class="bulletIndent1">The laparoscopic approach for adrenalectomy, which can be done via either the anterior or posterior approaches, has become standard as hospital stays appear to be shorter (usually one to five days) and complications fewer, as compared with open surgery. (See <a class="local">'Surgical approach'</a> above and  <a class="medical medical_review" href="/z/d/html/15027.html" rel="external">"Adrenalectomy techniques", section on 'Selection of operative approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative pituitary irradiation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with Cushing disease with radiologically detectable residual corticotroph tumor, we suggest pituitary irradiation prior to adrenalectomy to reduce the risk of Nelson syndrome (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Preoperative pituitary irradiation'</a> above and <a class="local">'Nelson syndrome'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients without residual tumor on pathology or MRI scan, we do not administer preventive radiotherapy, but perform regular MRI and ACTH measurements after adrenalectomy. (See <a class="local">'Postoperative management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assess for cure </strong>–<strong> </strong>Cure should be confirmed by measuring serum cortisol. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormone replacement </strong>– Glucocorticoid coverage is similar to that for transsphenoidal surgery, except that, in addition to lifelong glucocorticoid replacement, mineralocorticoid replacement with <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> must also be begun soon after surgery (<a class="graphic graphic_table graphicRef78904" href="/z/d/graphic/78904.html" rel="external">table 1</a>). (See <a class="local">'Hormone replacement'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitor for Nelson syndrome </strong>– Patients who have had bilateral adrenalectomy for Cushing disease may develop corticotroph tumor progression (Nelson syndrome). We monitor with MRI of the pituitary and plasma ACTH measurements, annually for seven years, and then intermittently if there has been no evidence of tumor progression. (See <a class="local">'Postoperative management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of Nelson syndrome </strong>–<strong> </strong>For patients who develop Nelson syndrome, we suggest early transsphenoidal surgery (before the tumor becomes a macroadenoma) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment is reviewed in detail above. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H169306535"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100:2807.</a></li><li><a class="nounderline abstract_t">Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. N Engl J Med 1971; 285:243.</a></li><li><a class="nounderline abstract_t">Moore TJ, Dluhy RG, Williams GH, Cain JP. Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 1976; 85:731.</a></li><li><a class="nounderline abstract_t">Kelly WF, MacFarlane IA, Longson D, et al. Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients. Q J Med 1983; 52:224.</a></li><li><a class="nounderline abstract_t">Aron DC, Schnall AM, Sheeler LR. Cushing's syndrome and pregnancy. Am J Obstet Gynecol 1990; 162:244.</a></li><li><a class="nounderline abstract_t">Thompson SK, Hayman AV, Ludlam WH, et al. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg 2007; 245:790.</a></li><li><a class="nounderline abstract_t">Hardy JD. Surgical management of Cushing's syndrome with emphasis on adrenal autotransplantation. Ann Surg 1978; 188:290.</a></li><li><a class="nounderline abstract_t">Young WF Jr, Thompson GB. Laparoscopic adrenalectomy for patients who have Cushing's syndrome. Endocrinol Metab Clin North Am 2005; 34:489.</a></li><li><a class="nounderline abstract_t">Smith PW, Turza KC, Carter CO, et al. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 2009; 208:1059.</a></li><li><a class="nounderline abstract_t">Vella A, Thompson GB, Grant CS, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:1596.</a></li><li><a class="nounderline abstract_t">Chalmers RA, Mashiter K, Joplin GF. Residual adrenocortical function after bilateral "total" adrenalectomy for Cushing's disease. Lancet 1981; 2:1196.</a></li><li><a class="nounderline abstract_t">Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 1997; 46:255.</a></li><li><a class="nounderline abstract_t">Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf) 1997; 46:263.</a></li><li><a class="nounderline abstract_t">Kemink SA, Frijns JT, Hermus AR, et al. Body composition determined by six different methods in women bilaterally adrenalectomized for treatment of Cushing's disease. J Clin Endocrinol Metab 1999; 84:3991.</a></li><li><a class="nounderline abstract_t">Oßwald A, Plomer E, Dimopoulou C, et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. Eur J Endocrinol 2014; 171:209.</a></li><li><a class="nounderline abstract_t">Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 2007; 92:172.</a></li><li><a class="nounderline abstract_t">Hopwood NJ, Kenny FM. Incidence of Nelson's syndrome after adrenalectomy for Cushing's disease in children: results of a nationwide survey. Am J Dis Child 1977; 131:1353.</a></li><li><a class="nounderline abstract_t">Kasperlik-Załuska AA, Nielubowicz J, Wisławski J, et al. Nelson's syndrome: incidence and prognosis. Clin Endocrinol (Oxf) 1983; 19:693.</a></li><li><a class="nounderline abstract_t">Kasperlik-Zaluska A, Walecki J, Brzeziński J, et al. MRI versus CT in the diagnosis of Nelson's syndrome. Eur Radiol 1997; 7:106.</a></li><li><a class="nounderline abstract_t">Kemink SA, Grotenhuis JA, De Vries J, et al. Management of Nelson's syndrome: observations in fifteen patients. Clin Endocrinol (Oxf) 2001; 54:45.</a></li><li><a class="nounderline abstract_t">Kasperlik-Załuska AA, Bonicki W, Jeske W, et al. Nelson's syndrome -- 46 years later: clinical experience with 37 patients. Zentralbl Neurochir 2006; 67:14.</a></li><li><a class="nounderline abstract_t">Sarkis P, Rabilloud M, Lifante JC, et al. Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options. Ann Endocrinol (Paris) 2019; 80:32.</a></li><li><a class="nounderline abstract_t">Mountjoy KG. The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides. Mol Cell Endocrinol 1994; 102:R7.</a></li><li><a class="nounderline abstract_t">Barber TM, Adams E, Ansorge O, et al. Nelson's syndrome. Eur J Endocrinol 2010; 163:495.</a></li><li><a class="nounderline abstract_t">Cohen KL, Noth RH, Pechinski T. Incidence of pituitary tumors following adrenalectomy. A long-term follow-up study of patients treated for Cushing's disease. Arch Intern Med 1978; 138:575.</a></li><li><a class="nounderline abstract_t">McArthur RG, Hayles AB, Salassa RM. Childhood Cushing disease: results of bilateral adrenalectomy. J Pediatr 1979; 95:214.</a></li><li><a class="nounderline abstract_t">Wilson CB, Tyrrell JB, Fitzgerald PA, Pitts LH. Cushing's disease and Nelson's syndrome. Clin Neurosurg 1980; 27:19.</a></li><li><a class="nounderline abstract_t">Pereira MA, Halpern A, Salgado LR, et al. A study of patients with Nelson's syndrome. Clin Endocrinol (Oxf) 1998; 49:533.</a></li><li><a class="nounderline abstract_t">Assié G, Bahurel H, Bertherat J, et al. The Nelson's syndrome... revisited. Pituitary 2004; 7:209.</a></li><li><a class="nounderline abstract_t">Papakokkinou E, Piasecka M, Carlsen HK, et al. Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis. Pituitary 2021; 24:797.</a></li><li><a class="nounderline abstract_t">Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 1979; 300:459.</a></li><li><a class="nounderline abstract_t">Schteingart DE, Tsao HS, Taylor CI, et al. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980; 92:613.</a></li><li><a class="nounderline abstract_t">Kemink SAG, Smals AGH, Hermus AR, et al. Nelson's syndrome: A review. Endocrinologist 1997; 7:5.</a></li><li><a class="nounderline abstract_t">Nagesser SK, van Seters AP, Kievit J, et al. Long-term results of total adrenalectomy for Cushing's disease. World J Surg 2000; 24:108.</a></li><li><a class="nounderline abstract_t">Ray DW, Gibson S, Crosby SR, et al. Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids. J Clin Endocrinol Metab 1995; 80:2430.</a></li><li><a class="nounderline abstract_t">Jenkins PJ, Trainer PJ, Plowman PN, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1995; 80:165.</a></li><li><a class="nounderline abstract_t">Karl M, Von Wichert G, Kempter E, et al. Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996; 81:124.</a></li><li><a class="nounderline abstract_t">Gil-Cárdenas A, Herrera MF, Díaz-Polanco A, et al. Nelson's syndrome after bilateral adrenalectomy for Cushing's disease. Surgery 2007; 141:147.</a></li><li><a class="nounderline abstract_t">Pinto EM, Siqueira SA, Cukier P, et al. Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome. Pituitary 2011; 14:400.</a></li><li><a class="nounderline abstract_t">Azad TD, Veeravagu A, Kumar S, Katznelson L. Nelson Syndrome: Update on Therapeutic Approaches. World Neurosurg 2015; 83:1135.</a></li><li><a class="nounderline abstract_t">Reincke M, Albani A, Assie G, et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 2021; 184:P1.</a></li><li><a class="nounderline abstract_t">De Tommasi C, Vance ML, Okonkwo DO, et al. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome. J Neurosurg 2005; 103:825.</a></li><li><a class="nounderline abstract_t">Kelly PA, Samandouras G, Grossman AB, et al. Neurosurgical treatment of Nelson's syndrome. J Clin Endocrinol Metab 2002; 87:5465.</a></li><li><a class="nounderline abstract_t">Howlett TA, Plowman PN, Wass JA, et al. Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up. Clin Endocrinol (Oxf) 1989; 31:309.</a></li><li><a class="nounderline abstract_t">Jane JA Jr, Vance ML, Woodburn CJ, Laws ER Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus 2003; 14:e12.</a></li><li><a class="nounderline abstract_t">Vik-Mo EO, Øksnes M, Pedersen PH, et al. Gamma knife stereotactic radiosurgery of Nelson syndrome. Eur J Endocrinol 2009; 160:143.</a></li><li><a class="nounderline abstract_t">Mauermann WJ, Sheehan JP, Chernavvsky DR, et al. Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy. J Neurosurg 2007; 106:988.</a></li><li><a class="nounderline abstract_t">Aronin N, Krieger DT. Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment. N Engl J Med 1980; 302:453.</a></li><li><a class="nounderline abstract_t">Mercado-Asis LB, Yanovski JA, Tracer HL, et al. Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome. J Clin Endocrinol Metab 1997; 82:514.</a></li><li><a class="nounderline abstract_t">Casulari LA, Naves LA, Mello PA, et al. Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment. Horm Res 2004; 62:300.</a></li><li><a class="nounderline abstract_t">Pivonello R, Faggiano A, Di Salle F, et al. Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999; 22:860.</a></li><li><a class="nounderline abstract_t">Andreassen M, Kristensen LØ. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur J Endocrinol 2005; 153:503.</a></li><li><a class="nounderline abstract_t">Munir A, Song F, Ince P, et al. Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 2007; 92:1758.</a></li><li><a class="nounderline abstract_t">Mullan KR, Leslie H, McCance DR, et al. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 2006; 64:519.</a></li><li><a class="nounderline abstract_t">Kreutzer J, Jeske I, Hofmann B, et al. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo. Clin Neuropathol 2009; 28:430.</a></li><li><a class="nounderline abstract_t">Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95:4592.</a></li></ol></div><div id="topicVersionRevision">Topic 16322 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222757" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4326256" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Results of treatment in 108 patients with Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/999109" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nelson's syndrome: frequency, prognosis, and effect of prior pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6310673" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cushing's disease treated by total adrenalectomy: long-term observations of 43 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405679" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cushing's syndrome and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457173" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/686895" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Surgical management of Cushing's syndrome with emphasis on adrenal autotransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15850855" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Laparoscopic adrenalectomy for patients who have Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19476892" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11297589" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6118630" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Residual adrenocortical function after bilateral "total" adrenalectomy for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156031" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glucocorticoid replacement therapy: are patients over treated and does it matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9156032" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An assessment of optimal hydrocortisone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566639" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Body composition determined by six different methods in women bilaterally adrenalectomized for treatment of Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975318" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062771" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/930887" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Incidence of Nelson's syndrome after adrenalectomy for Cushing's disease in children: results of a nationwide survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317234" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Nelson's syndrome: incidence and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9000409" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : MRI versus CT in the diagnosis of Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167925" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Management of Nelson's syndrome: observations in fifteen patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16518746" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nelson's syndrome -- 46 years later: clinical experience with 37 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243473" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7926261" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The human melanocyte stimulating hormone receptor has evolved to become "super-sensitive" to melanocortin peptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668020" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/637638" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Incidence of pituitary tumors following adrenalectomy. A long-term follow-up study of patients treated for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/448561" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Childhood Cushing disease: results of bilateral adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7273554" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cushing's disease and Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9876353" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A study of patients with Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132203" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The Nelson's syndrome... revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34036460" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/215912" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6247946" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Sustained remission of Cushing's disease with mitotane and pituitary irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nelson's syndrome: A review</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10594213" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term results of total adrenalectomy for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629238" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Elevated levels of adrenocorticotropin (ACTH) precursors in post-adrenalectomy Cushing's disease and their regulation by glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7829606" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8550738" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17263968" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Nelson's syndrome after bilateral adrenalectomy for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655257" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Possible role of a radiation-induced p53 mutation in a Nelson's syndrome patient with a fatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25683128" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nelson Syndrome: Update on Therapeutic Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33444221" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304985" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466338" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neurosurgical treatment of Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2559823" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Megavoltage pituitary irradiation in the management of Cushing's disease and Nelson's syndrome: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15669808" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18996962" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gamma knife stereotactic radiosurgery of Nelson syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17564169" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gamma Knife surgery for adrenocorticotropic hormone-producing pituitary adenomas after bilateral adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6243392" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sustained remission of Nelson's syndrome after stopping cyproheptadine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024246" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557761" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710275" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189170" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17311852" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ineffectiveness of rosiglitazone therapy in Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16649970" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19919817" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660056" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
